Cargando…
A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern
Emerging severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) variants, especially the Omicron variant, have impaired the efficacy of existing vaccines and most therapeutic antibodies, highlighting the need for additional antibody-based tools that can efficiently neutralize emerging SAR...
Autores principales: | Yuan, Mengqi, Chen, Xiangyu, Zhu, Yanzhi, Dong, Xiaoqing, Liu, Yan, Qian, Zhaohui, Ye, Lilin, Liu, Pinghuang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400488/ https://www.ncbi.nlm.nih.gov/pubmed/35916510 http://dx.doi.org/10.1128/jvi.00775-22 |
Ejemplares similares
-
A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection
por: Shi, Juan, et al.
Publicado: (2022) -
An RBD bispecific antibody effectively neutralizes a SARS-CoV-2 Omicron variant
por: Yuan, Mengqi, et al.
Publicado: (2023) -
SARS-CoV-2 Spike Protein Stabilized in the Closed State Induces Potent Neutralizing Responses
por: Carnell, George W., et al.
Publicado: (2021) -
Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer
por: Zhan, Wuqiang, et al.
Publicado: (2022) -
Potent Neutralization of SARS-CoV-2 by Hetero-Bivalent Alpaca Nanobodies Targeting the Spike Receptor-Binding Domain
por: Ma, Huan, et al.
Publicado: (2021)